TY - JOUR
T1 - Panel 1
T2 - Biotechnology, biomedical engineering and new models of otitis media
AU - Gisselsson-Solén, Marie
AU - Tähtinen, Paula A.
AU - Ryan, Allen F.
AU - Mulay, Apoorva
AU - Kariya, Shin
AU - Schilder, Anne G.M.
AU - Valdez, Tulio A.
AU - Brown, Steve
AU - Nolan, Ryan M.
AU - Hermansson, Ann
AU - van Ingen, Gijs
AU - Marom, Tal
N1 - Funding Information:
Ryan M. Nolan, is the Co-Founder and VP of Clinical Operations, PhotoniCare, Inc. Tal Marom and Anne G.M. Schilder are on the Scientific Advisory Board of Novus Therapeutics, Inc. Allen F. Ryan is a Co-founder of and stockholder in Otonomy, Inc. The other authors declare no conflicts of interest, and there has been no financial support received for this work. Funding for the generation and publication of this panel report was made possible in part by 1 R13 DC017389-01 from the National Institute on Deafness and Other Communication Disorders .
PY - 2020/3
Y1 - 2020/3
N2 - Objective: To summarize recently published key articles on the topics of biomedical engineering, biotechnology and new models in relation to otitis media (OM). Data sources: Electronic databases: PubMed, Ovid Medline, Cochrane Library and Clinical Evidence (BMJ Publishing). Review methods: Articles on biomedical engineering, biotechnology, material science, mechanical and animal models in OM published between May 2015 and May 2019 were identified and subjected to review. A total of 132 articles were ultimately included. Results: New imaging technologies for the tympanic membrane (TM) and the middle ear cavity are being developed to assess TM thickness, identify biofilms and differentiate types of middle ear effusions. Artificial intelligence (AI) has been applied to train software programs to diagnose OM with a high degree of certainty. Genetically modified mice models for OM have further investigated what predisposes some individuals to OM and consequent hearing loss. New vaccine candidates protecting against major otopathogens are being explored and developed, especially combined vaccines, targeting more than one pathogen. Transcutaneous vaccination against non-typeable Haemophilus influenzae has been successfully tried in a chinchilla model. In terms of treatment, novel technologies for trans-tympanic drug delivery are entering the clinical domain. Various growth factors and grafting materials aimed at improving healing of TM perforations show promising results in animal models. Conclusion: New technologies and AI applications to improve the diagnosis of OM have shown promise in pre-clinical models and are gradually entering the clinical domain. So are novel vaccines and drug delivery approaches that may allow local treatment of OM. IMPLICATIONS FOR PRACTICE: New diagnostic methods, potential vaccine candidates and the novel trans-tympanic drug delivery show promising results, but are not yet adapted to clinical use.
AB - Objective: To summarize recently published key articles on the topics of biomedical engineering, biotechnology and new models in relation to otitis media (OM). Data sources: Electronic databases: PubMed, Ovid Medline, Cochrane Library and Clinical Evidence (BMJ Publishing). Review methods: Articles on biomedical engineering, biotechnology, material science, mechanical and animal models in OM published between May 2015 and May 2019 were identified and subjected to review. A total of 132 articles were ultimately included. Results: New imaging technologies for the tympanic membrane (TM) and the middle ear cavity are being developed to assess TM thickness, identify biofilms and differentiate types of middle ear effusions. Artificial intelligence (AI) has been applied to train software programs to diagnose OM with a high degree of certainty. Genetically modified mice models for OM have further investigated what predisposes some individuals to OM and consequent hearing loss. New vaccine candidates protecting against major otopathogens are being explored and developed, especially combined vaccines, targeting more than one pathogen. Transcutaneous vaccination against non-typeable Haemophilus influenzae has been successfully tried in a chinchilla model. In terms of treatment, novel technologies for trans-tympanic drug delivery are entering the clinical domain. Various growth factors and grafting materials aimed at improving healing of TM perforations show promising results in animal models. Conclusion: New technologies and AI applications to improve the diagnosis of OM have shown promise in pre-clinical models and are gradually entering the clinical domain. So are novel vaccines and drug delivery approaches that may allow local treatment of OM. IMPLICATIONS FOR PRACTICE: New diagnostic methods, potential vaccine candidates and the novel trans-tympanic drug delivery show promising results, but are not yet adapted to clinical use.
KW - Animal model
KW - Diagnostics
KW - Haemophilus influenzae
KW - Moraxella catarrhalis
KW - Otitis media
KW - Streptococcus pneumoniae
KW - Treatment
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85077165747&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077165747&partnerID=8YFLogxK
U2 - 10.1016/j.ijporl.2019.109833
DO - 10.1016/j.ijporl.2019.109833
M3 - Article
C2 - 31901291
AN - SCOPUS:85077165747
VL - 130
JO - International Journal of Pediatric Otorhinolaryngology
JF - International Journal of Pediatric Otorhinolaryngology
SN - 0165-5876
M1 - 109833
ER -